IDENTIFICATION OF MULTI-MODAL ASSOCIATIONS BETWEEN BIOMEDICAL MARKERS
    1.
    发明申请
    IDENTIFICATION OF MULTI-MODAL ASSOCIATIONS BETWEEN BIOMEDICAL MARKERS 审中-公开
    鉴定生物医学标记之间的多模式协会

    公开(公告)号:US20130196877A1

    公开(公告)日:2013-08-01

    申请号:US13877346

    申请日:2011-10-04

    IPC分类号: G06F19/20

    CPC分类号: G16B25/00 G16B5/00 G16B20/00

    摘要: The present invention relates to a method for identifying multi-modal associations between biomedical markers which allows for the determination of network nodes and/or high ranking network members or combinations thereof, indicative of having a diagnostic, prognostic or predictive value for a medical condition, in particular ovarian cancer. The present invention further relates to a biomedical marker or group of biomedical markers associated with a high likelihood of responsiveness of a subject to a cancer therapy, preferably a platinum based cancer therapy, wherein said bio-medical marker or group of biomedical markers comprises at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 8, 19, 20 or all markers selected from PKMYT1, SKIL, RAB8A, HIRIP3, CTNNB1, NGFR, ZCCHC11, LSP1, CD200, PAX8, CYBRD1, HOXC11, TCEAL1, FZD10,FZD1, BBS4, IRS2, TLX3, TSPAN2, TXN, and CFLAR. Furthermore, an assay for detecting, diagnosing, graduating, monitoring or prognosticating a medical condition, or for detecting, 1 diagnosing, monitoring or prognosticating the responsiveness of a subject to a therapy against said medical condition, in particular ovarian cancer, is provided, as well as a corresponding method for classifying a subject comprising and a medical decision support system.

    摘要翻译: 本发明涉及一种用于识别生物医学标记之间的多模式关联的方法,其允许确定网络节点和/或高排名网络成员或其组合,指示具有用于医疗状况的诊断,预后或预测值, 特别是卵巢癌。 本发明还涉及与受试者对癌症治疗(优选基于铂的癌症治疗)的高反应性的高可能性相关联的生物医学标记物或生物医学标记物组,其中所述生物医学标记物或生物医学标记物组至少包括 1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,8,19,20或选自PKMYT1,SKIL,RAB8A, HIRIP3,CTNNB1,NGFR,ZCCHC11,LSP1,CD200,PAX8,CYBRD1,HOXC11,TCEAL1,FZD10,FZD1,BBS4,IRS2,TLX3,TSPAN2,TXN和CFLAR。 此外,提供了用于检测,诊断,毕业,监测或预测医学状况或用于检测1诊断,监测或预测受试者对于针对所述医学病症,特别是卵巢癌的治疗的反应性的测定法,作为 以及用于分类受试者的相应方法以及医疗决策支持系统。

    METHOD FOR THE DETECTION OF DNA METHYLATION PATTERNS
    2.
    发明申请
    METHOD FOR THE DETECTION OF DNA METHYLATION PATTERNS 审中-公开
    检测DNA甲基化模式的方法

    公开(公告)号:US20120053071A1

    公开(公告)日:2012-03-01

    申请号:US13140972

    申请日:2009-12-14

    CPC分类号: C12Q1/6827 C12Q2523/125

    摘要: The present invention relates to a method for the detection of a DNA methylation signature associated with the presence of or the predisposition to develop a disorder, the method comprising the identification of one or more candidate genes exhibiting differential DNA methylation in target and reference samples as well as the respective determination of the nucleic acid sites in said candidate genes that are differentially methylated and the recognition sites for DNA binding factors, said DNA binding factors each recognizing such a differentially methylated nucleic acid site, wherein the patterns of differentially methylated nucleic acid sites and of DNA binding factor recognition sites obtained together represent a DNA methylation signature that is indicative for the presence of or the predisposition to develop a disorder in a target sample.

    摘要翻译: 本发明涉及一种用于检测与发生病症的存在或倾向相关的DNA甲基化特征的方法,所述方法包括鉴定靶和参照样品中显示差异DNA甲基化的一个或多个候选基因 作为差异甲基化的所述候选基因中的核酸位点和DNA结合因子的识别位点的各自测定,所述DNA结合因子各自识别这样的差异甲基化核酸位点,其中差异甲基化的核酸位点和 一起获得的DNA结合因子识别位点代表一种DNA甲基化特征,其指示在目标样品中存在发生障碍的倾向或倾向。

    Identification of multi-modal associations between biomedical markers

    公开(公告)号:US10340027B2

    公开(公告)日:2019-07-02

    申请号:US13877346

    申请日:2011-10-04

    摘要: The present invention relates to a method for identifying multi-modal associations between biomedical markers which allows for the determination of network nodes and/or high ranking network members or combinations thereof, indicative of having a diagnostic, prognostic or predictive value for a medical condition, in particular ovarian cancer. The present invention further relates to a biomedical marker or group of biomedical markers associated with a high likelihood of responsiveness of a subject to a cancer therapy, preferably a platinum based cancer therapy, wherein said biomedical marker or group of biomedical markers comprises at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 8, 19, 20 or all markers selected from PKMYT1, SKIL, RAB8A, HIRIP3, CTNNB1, NGFR, ZCCHC11, LSP1, CD200, PAX8, CYBRD1, HOXC11, TCEAL1, FZD10, FZD1, BBS4, IRS2, TLX3, TSPAN2, TXN, and CFLAR. Furthermore, an assay for detecting, diagnosing, graduating, monitoring or prognosticating a medical condition, or for detecting, 1 diagnosing, monitoring or prognosticating the responsiveness of a subject to a therapy against said medical condition, in particular ovarian cancer, is provided, as well as a corresponding method for classifying a subject comprising and a medical decision support system.

    METHOD FOR ESTIMATION OF INFORMATION FLOW IN BIOLOGICAL NETWORKS
    6.
    发明申请
    METHOD FOR ESTIMATION OF INFORMATION FLOW IN BIOLOGICAL NETWORKS 审中-公开
    生物网络信息流估计方法

    公开(公告)号:US20140040264A1

    公开(公告)日:2014-02-06

    申请号:US13983651

    申请日:2012-01-30

    IPC分类号: G06F19/00

    摘要: The present invention relates to a method for stratifying a patient into a clinically relevant group comprising the identification of the probability of an alteration within one or more sets of molecular data from a patient sample in comparison to a database of molecular data of known phenotypes, the inference of the activity of a biological network on the basis of the probabilities, the identification of a network information flow probability for the patient via the probability of interactions in the network, the creation of multiple instances of network information flow for the patient sample and the calculation of the distance of the patient from other subjects in a patient database using multiple instances of the network information flow. The invention further relates to a biomedical marker or group of biomedical markers associated with a high likelihood of responsiveness of a subject to a cancer therapy wherein the biomedical marker or group of biomedical markers comprises altered biological pathway markers, as well as to an assay for detecting, diagnosing, graduating, monitoring or prognosticating a medical condition, or for detecting, diagnosing, monitoring or prognosticating the responsiveness of a subject to a therapy against said medical condition, in particular ovarian cancer. Furthermore, a corresponding clinical decision support system is provided.

    摘要翻译: 本发明涉及一种用于将患者分层为临床相关组的方法,其包括鉴定来自患者样品的一组或多组分子数据内的改变概率与已知表型的分子数据的数据库相比较, 基于概率推断生物网络的活动,通过网络中的交互概率识别患者的网络信息流概率,创建患者样本的多个网络信息流实例和 使用网络信息流的多个实例来计算患者与患者数据库中的其他受试者的距离。 本发明进一步涉及生物医学标记物或生物医学标记物组,其与受试者对癌症治疗的响应性的高可能性相关联,其中生物医学标记物或生物医学标记物组包括改变的生物学途径标志物,以及用于检测 ,诊断,毕业,监测或预测医学状况,或用于检测,诊断,监测或预测受试者对于针对所述医学病症,特别是卵巢癌的治疗的反应性。 此外,提供了相应的临床决策支持系统。

    METHOD FOR THE ANALYSIS OF BREAST CANCER DISORDERS
    8.
    发明申请
    METHOD FOR THE ANALYSIS OF BREAST CANCER DISORDERS 审中-公开
    乳腺癌分析方法

    公开(公告)号:US20100279879A1

    公开(公告)日:2010-11-04

    申请号:US12678628

    申请日:2008-09-16

    摘要: Method for the analysis of breast cancer disorders, comprising determining the genomic methylation status of one or more CpG dinucleotides in a sequence selected from the group of sequences according to SEQ ID NO. 1 to 10 and/or SEQ ID NO. 50 to SEQ ID NO. 60. Optionally, additionally following steps are performed, the one or more results from the methylation status test is input into a classifier that is obtained from a Diagnostic Multi Variate Model, calculating a likelihood as to whether the sample is from a normal tissue or an breast cancer tissue and/or, calculating an associated p-value for the confidence in the prediction.

    摘要翻译: 用于分析乳腺癌病症的方法,包括确定一个或多个CpG二核苷酸的基因组甲基化状态,所述序列选自SEQ ID NO。 1至10和/或SEQ ID NO。 50至SEQ ID NO。 可选地,另外执行以下步骤,将来自甲基化状态测试的一个或多个结果输入到从诊断多变量模型获得的分类器中,计算样品是来自正常组织或 乳腺癌组织和/或计算预测中置信度的相关p值。

    INTEGRATED ACCESS TO AND INTERATION WITH MULTIPLICITY OF CLINICA DATA ANALYTIC MODULES
    9.
    发明申请
    INTEGRATED ACCESS TO AND INTERATION WITH MULTIPLICITY OF CLINICA DATA ANALYTIC MODULES 审中-公开
    综合访问和与临床数据分析模块的多重性相关联

    公开(公告)号:US20130282404A1

    公开(公告)日:2013-10-24

    申请号:US13976170

    申请日:2012-01-04

    IPC分类号: G06F19/00

    摘要: A state machine (22) stores a current state (30) comprising a clinical context defined by available patient-related information relating to a medical patient, and identifies one or more available analytical tools of a set of analytical tools (24) that are applicable to the current state. A graphical user interface module (16) receives a user selection of an available analytical tool. The state machine loads patient-related information (40) to the user-selected available analytical tool (24sel) and invokes the user-selected available analytical tool to operate on the loaded patient-related information to generate additional patient-related information relating to the medical patient and/or graphical patient-related content relating to the medical patient. The state machine transitions from the current state (30) to a next state (30′) and/or invokes the graphical user interface module to display the graphical patient related content.

    摘要翻译: 状态机(22)存储当前状态(30),其包括由与医疗患者有关的可用患者相关信息定义的临床上下文,并且识别可应用的一组分析工具(24)中的一个或多个可用分析工具 到目前状态。 图形用户界面模块(16)接收可用分析工具的用户选择。 状态机将患者相关信息(40)加载到用户选择的可用分析工具(24sel),并且调用用户选择的可用分析工具对所加载的患者相关信息进行操作,以生成与患者相关的附加信息 与患者有关的医疗病人和/或图形患者相关内容。 状态机从当前状态(30)转换到下一状态(30')和/或调用图形用户界面模块以显示图形的患者相关内容。